Demethylation demystification.

Abstract

The ability of the DNA methyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 1979; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993. That azacitidine improves survival in patients with high-risk MDS and acute myeloid leukemia with MDS features compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15% of patients makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?

• Authors: Lauren Suarez, Steven D Gore
• Journal: Blood (Blood) Vol. 121 Issue 9 Pg. 1488-9 (Feb 28 2013) ISSN: 1528-0020 [Electronic] United States
• PMID: 23449614 (Publication Type: Journal Article, Comment)

Chemical References

• Decitabine
• Azacitidine

Topics

• Animals
• Azacitidine (analogs & derivatives, pharmacology)
• Decitabine
• Gene Expression Regulation, Leukemic (drug effects)
• Humans
• Leukemia, Myeloid, Acute (genetics)